Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CG0009 is a potent and highly selective glycogen synthase kinase 3 (GSK3) inhibitor that inhibitions proliferation, induces apoptosis, and activates the p53-Bax pathway in breast cancer cells through cyclin D1 depletion. CG0009 inhibit breast cancer cell growth through cyclin D1 depletion and p53 activation, and thus may provide an innovative treatment approach for breast cancer resistant to hormone-based therapies.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | CG0009 is a potent and highly selective glycogen synthase kinase 3 (GSK3) inhibitor that inhibitions proliferation, induces apoptosis, and activates the p53-Bax pathway in breast cancer cells through cyclin D1 depletion. CG0009 inhibit breast cancer cell growth through cyclin D1 depletion and p53 activation, and thus may provide an innovative treatment approach for breast cancer resistant to hormone-based therapies. |
Synonyms | CG-0009, CG 0009 |
Molecular Weight | 457.57 |
Formula | C26H31N7O |
CAS No. | 944744-57-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CG0009 944744-57-4 CG-0009 CG 0009 inhibitor inhibit